GlassScriptPhysician profile
Danielle H Wang
NPI 1679928881
$2,342.64
in general payments reported to CMS, 2019-2025
12 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2021: $270 · 2022: $888 · 2023: $265 · 2024: $283 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,045.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,115.03 | 2022-2025 | Rinvoq, Skyrizi |
| Glaxosmithkline, LLC. | $442.93 | 2021-2022 | |
| Amgen INC. | $178.11 | 2019-2025 | Krystexxa |
| Janssen Scientific Affairs, LLC | $150.00 | 2022 | |
| Aurinia Pharma U.S., INC. | $120.79 | 2024 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $118.18 | 2022 | |
| Janssen Biotech, INC. | $100.78 | 2023 | Simponi Aria |
| Ambu INC. | $51.20 | 2022 | |
| Depuy Synthes Sales INC. | $22.64 | 2021 | |
| Verrica Pharmaceuticals INC. | $15.79 | 2024 | Ycanth |
| Genzyme Corporation | $14.96 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.